Delving into the Latest Updates on Porcine Fibrin (Guangzhou Baitejing Pharmaceutical Technology) with Synapse

Overview

Basic Info

Drug Type

Blood components

Synonyms

DBT, Porcine Fibrin Sealant Patch

Target

fibrin

Action

modulators

Mechanism

fibrin modulators(Fibrin modulators)

Therapeutic Areas

Other Diseases

Active Indication

Postoperative Hemorrhage

Inactive Indication-

Originator Organization

Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.

Guangzhou Zhongwei Biotechnology Co., Ltd.

Active Organization

Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.

Guangzhou Zhongwei Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Organotin (OT) compounds are commonly used in antifouling paints, but can cause toxic effects in various marine organisms, including gastropods, amphibians, and teleosts. The effects of these chemicals on marine mammals remain largely unknown. We comprehensively investigated the accumulation patterns and health risks of six OTs in Indo-Pacific finless porpoises (Neophocaena phocaenoides) from the Pearl River Estuary (PRE), China, from 2007 to 2020. Six OTs were detected in all the finless porpoise samples, with tributyltin (TPT) and dibutyltin (DBT) being the dominant chemicals in the liver and muscle, respectively. The mean hepatic concentration of TPT (516.1 ng g^-1 wet weight) exceeded the levels reported for cetaceans from other regions. Despite the observed decreasing trends of butyltins (BTs) in recent years, which aligns with the global restriction of OT-based antifouling paints since 2008, phenyltins (PTs) have continued to increase in porpoise tissues, suggesting continued deposition of PTs in the PRE. In vitro, the tissue-relative concentrations of TPT, tributyltin, and DBT-induced lipid disruption by activating the finless porpoise peroxisome proliferator-activated receptor α/γ (npPPARα/γ). In silico simulations further revealed a higher toxic potential of PTs than BTs on npPPARα/γ. Our results underscore the urgency for further monitoring and elimination of PTs in China.

24 Mar 2025·Journal of Medical Imaging

Investigating the effect of adding comparisons with prior mammograms to standalone digital breast tomosynthesis screening

Article

Author: Hellgren, Gustav ; Timberg, Pontus ; Dustler, Magnus ; Tingberg, Anders

PurposeThe purpose is to retrospectively investigate how the addition of prior and concurrent mammograms affects wide-angle digital breast tomosynthesis (DBT) screening false-positive recall rates, malignancy scoring, and recall agreement.ApproachA total of 200 cases were selected from the Malmö Breast Tomosynthesis Screening Trial. They consist of 150 recalled cases [30 true positives (TPs), 120 false positives (FPs), and 50 healthy, non-recalled true-negative (TN) cases]. The positive cases were categorized based on being recalled by either DBT, digital mammography (DM), or both. Each case had DBT, synthetic mammography (SM), and DM (prior screening round) images. Five radiologists participated in a reading study where detection, risk of malignancy, and recall were assessed. They read each case twice, once using only DBT and once using DBT together with SM and DM priors.ResultsThe results showed a significant reduction in recall rates for all FP categories, as well as for the TN cases, when adding SM and prior DM to DBT. This resulted also in a significant increase in recall agreement for these categories, with more of the negative cases being recalled by few or no readers. These categories were overall rated as appearing more malignant in the DBT reading arm. For the TP categories, there was a significant decrease in recalls for DM-recalled cancers ( __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__p = 0.047 ), but no significant difference for DBT-recalled cancers ( __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__p = 0.063 ), or DBT/DM-recalled cancers ( __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__p = 0.208 ).ConclusionsSimilar to the documented effect of priors in DM screening, we suggest that added two-dimensional priors improve the specificity of DBT screening but may reduce the sensitivity.

01 Mar 2025·Clinical and Translational Science

Comparative Effectiveness of Dual Biologic Therapy and Biologic Small‐Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single‐Center Study

Article

Author: Feng, Xin ; Chen, Min ; Liu, Xiaolei ; Li, Songbo ; Shi, Yongquan ; Yin, Fan ; He, Dongdong

ABSTRACTPatients with refractory inflammatory bowel disease (IBD) face difficulty in the treatment strategy. Combined advanced targeted therapies may obtain higher therapeutic efficacy. However, few studies compare the efficacy and safety of dual biologic therapy (DBT) with biologic small‐molecule therapy (BMT) for refractory IBD. We aimed to compare the effectiveness of DBT with BMT. We retrospectively analyzed the data of patients with refractory IBD treated with DBT (n = 22) or BMT (n = 21). The primary outcome was the clinical remission rate at week 12. Secondary outcomes included the clinical response rate, endoscopic response rate, endoscopic remission rate, colectomy rate, and rate of adverse events (AEs) at week 12. At week 12, the clinical remission rates in the DBT group and BMT group were 22.7% and 28.6%, respectively. No statistically significant difference was observed between the two groups (p = 0.661). There were also no statistically significant differences between the DBT group and BMT group in the clinical response rate (68.2% vs. 71.4%, p = 0.817), endoscopic response rate (66.7% vs. 68.8%, p = 1.000), endoscopic remission rate (4.8% vs. 18.8%, p = 0.296) and colectomy rate (4.5% vs. 23.8%, p = 0.167). Two patients (9.5%) in the BMT group and no patients in the DBT group experienced AEs. However, the difference was not statistically significant (p = 0.233). In conclusion, this study revealed that there may be similar effectiveness and safety of DBT and BMT for patients with refractory IBD. Further multi‐center, prospective randomized controlled trials are necessary to confirm this conclusion.

100 Deals associated with Porcine Fibrin (Guangzhou Baitejing Pharmaceutical Technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postoperative Hemorrhage	Phase 2	China	Guangzhou Baitejing Pharmaceutical Technology Co., Ltd.	30 Dec 2021
Postoperative Hemorrhage	Phase 2	China	Guangzhou Zhongwei Biotechnology Co., Ltd.	30 Dec 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data